Study Updated 03/05/2024
Study Website: PRECIDENTD
ClinicalTrials.gov#: NCT05390892
Study Design: Interventional
PCORnet Infrastructure: Collaboration, CDM (+supplemental data), Engagement, Single IRB
Principal Investigator: Brendan Everett
Site Name: Brigham and Women’s Hospital
PCORnet® Network Partner: External
Funder: Patient-Centered Outcomes Research Institute (PCORI)
Funding Date: 2021
Study Duration: 2022 – 2028
Participating Clinical Research Networks: GPC, INSIGHT, PaTH, STAR
Therapeutic Area: Cardiovascular
Condition: Type2Diabetes; Atherosclerotic Cardiovascular Disease (ASCVD)
Population: 40 Years to 80 Years (Adult, Older Adult)
Status: Recruiting
Research Question(s):
- In patients with type 2 diabetes, are SGLT2 inhibitors or GLP-1 recent agonists better for preventing heart attack, stroke, blood vessel disease, heart failure, kidney disease, and death?
- Is combination therapy with both medication classes better than one therapy alone?